Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.

Zhang F, Tong Y, Su N, Li Y, Tang L, Huang L, Tong N.

J Diabetes. 2015 May;7(3):329-39. doi: 10.1111/1753-0407.12198. Epub 2014 Sep 10. Review.

PMID:
25043423
2.

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.

BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771. Review.

3.
4.

Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.

Su N, Li Y, Xu T, Li L, Kwong JS, Du H, Ren K, Li Q, Li J, Sun X, Li S, Tian H.

Int J Cardiol. 2016 Sep 15;219:293-300. doi: 10.1016/j.ijcard.2016.06.028. Epub 2016 Jun 15. Review.

PMID:
27343423
5.

Green tea for weight loss and weight maintenance in overweight or obese adults.

Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD008650. doi: 10.1002/14651858.CD008650.pub2. Review.

PMID:
23235664
6.

Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.

Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, Zhang Y, Ji L, Zhan S.

J Diabetes Res. 2015;2015:157201. doi: 10.1155/2015/157201. Epub 2015 Jan 20. Review.

7.

Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.

Wang Y, Li L, Yang M, Liu H, Boden G, Yang G.

Diabetes Obes Metab. 2011 Nov;13(11):972-81. doi: 10.1111/j.1463-1326.2011.01436.x. Review. Erratum in: Diabetes Obes Metab. 2014 Mar;16(3):285.

PMID:
21651690
8.

Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.

Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, Rajagopalan S.

Am J Hypertens. 2014 Jan;27(1):130-9. doi: 10.1093/ajh/hpt196. Epub 2013 Nov 21. Review.

PMID:
24263424
9.

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.

Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S.

Diabetes Res Clin Pract. 2015 Oct;110(1):26-37. doi: 10.1016/j.diabres.2015.07.015. Epub 2015 Aug 13. Review.

PMID:
26358202
10.

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.

Monami M, Marchionni N, Mannucci E.

Eur J Endocrinol. 2009 Jun;160(6):909-17. doi: 10.1530/EJE-09-0101. Epub 2009 Mar 24.

11.

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E.

Exp Diabetes Res. 2012;2012:672658. doi: 10.1155/2012/672658. Epub 2012 May 20.

12.

GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.

Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jørgensen NR, Jensen JE, Holst JJ, Madsbad S, Torekov SS.

J Clin Endocrinol Metab. 2015 Aug;100(8):2909-17. doi: 10.1210/jc.2015-1176. Epub 2015 Jun 4.

PMID:
26043228
13.

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.

Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.

Diabetes Obes Metab. 2013 Aug;15(8):737-49. doi: 10.1111/dom.12085. Epub 2013 Mar 20.

PMID:
23433305
14.

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ.

Obesity (Silver Spring). 2011 Jul;19(7):1342-9. doi: 10.1038/oby.2011.50. Epub 2011 Mar 17.

15.

Glucagon-like peptide analogues for type 2 diabetes mellitus.

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD006423. doi: 10.1002/14651858.CD006423.pub2. Review.

PMID:
21975753
16.
17.

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH.

PLoS One. 2015 Jun 29;10(6):e0126769. doi: 10.1371/journal.pone.0126769. eCollection 2015. Review.

18.

Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.

Ottney A.

Am J Health Syst Pharm. 2013 Dec 1;70(23):2097-103. doi: 10.2146/ajhp130081. Review.

PMID:
24249759
19.

Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.

Li WX, Gou JF, Tian JH, Yan X, Yang L.

Curr Ther Res Clin Exp. 2010 Aug;71(4):211-38. doi: 10.1016/j.curtheres.2010.08.003. Review.

20.

Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.

Feng P, Yu DM, Chen LM, Chang BC, Ji QD, Li SY, Zhu M, Ding SH, Zhang BZ, Wang SL, Li HT, Lin JN, Wang MJ, Guo JC, Liu J, Liu ZD, Wu ST, Yang JH.

Acta Pharmacol Sin. 2015 Feb;36(2):200-8. doi: 10.1038/aps.2014.136. Epub 2015 Jan 26.

Supplemental Content

Support Center